# KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer

> **NCT05027867** · PHASE2 · TERMINATED · sponsor: **Kartos Therapeutics, Inc.** · enrollment: 3 (actual)

## Conditions studied

- Small-cell Lung Cancer
- Small Cell Lung Carcinoma
- Small Cell Lung Cancer Extensive Stage
- Small Cell Lung Cancer Recurrent

## Interventions

- **DRUG:** KRT-232

## Key facts

- **NCT ID:** NCT05027867
- **Lead sponsor:** Kartos Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-12-06
- **Primary completion:** 2022-08-26
- **Final completion:** 2022-08-26
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Unanticipated and extremely high screen failure rate. There was no evidence of safety concerns in the study.
- **Last updated:** 2023-08-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05027867

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05027867, "KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05027867. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*